Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 9 |
| List of Tables | 9 | 1 |
| List of Figures | 10 | 1 |
| Introduction | 11 | 1 |
| Global Markets Direct Report Coverage | 11 | 1 |
| Uveitis Overview | 12 | 1 |
| Therapeutics Development | 13 | 2 |
| Pipeline Products for Uveitis Overview | 13 | 1 |
| Pipeline Products for Uveitis Comparative Analysis | 14 | 1 |
| Uveitis Therapeutics under Development by Companies | 15 | 4 |
| Uveitis Therapeutics under Investigation by Universities/Institutes | 19 | 1 |
| Uveitis Pipeline Products Glance | 20 | 3 |
| Late Stage Products | 20 | 1 |
| Clinical Stage Products | 21 | 1 |
| Early Stage Products | 22 | 1 |
| Uveitis Products under Development by Companies | 23 | 3 |
| Uveitis Products under Investigation by Universities/Institutes | 26 | 1 |
| Uveitis Companies Involved in Therapeutics Development | 27 | 34 |
| 2-BBB Medicines BV | 27 | 1 |
| AbbVie Inc | 28 | 1 |
| Aciont Inc. | 29 | 1 |
| Aldeyra Therapeutics Inc | 30 | 1 |
| Apitope International NV | 31 | 1 |
| Astellas Pharma Inc. | 32 | 1 |
| Bionomics Limited | 33 | 1 |
| Bristol-Myers Squibb Company | 34 | 1 |
| Can-Fite BioPharma Ltd. | 35 | 1 |
| Clearside BioMedical, Inc. | 36 | 1 |
| Endocyte, Inc. | 37 | 1 |
| Enzo Biochem, Inc. | 38 | 1 |
| EyeGate Pharmaceuticals, Inc. | 39 | 1 |
| F. Hoffmann-La Roche Ltd. | 40 | 1 |
| HanAll Biopharma Co., Ltd. | 41 | 1 |
| Icon Bioscience, Inc. | 42 | 1 |
| KPI Therapeutics, Inc. | 43 | 1 |
| Midatech Pharma Plc | 44 | 1 |
| Mitotech S.A. | 45 | 1 |
| Neuroptis Biotech | 46 | 1 |
| Novartis AG | 47 | 1 |
| Oculis ehf | 48 | 1 |
| OncoNOx ApS | 49 | 1 |
| OSE Immunotherapeutics | 50 | 1 |
| Palatin Technologies, Inc. | 51 | 1 |
| Panoptes Pharma Ges.m.b.H. | 52 | 1 |
| Pfizer Inc. | 53 | 1 |
| Precision Ocular Ltd | 54 | 1 |
| pSivida Corp. | 55 | 1 |
| Regeneron Pharmaceuticals Inc | 56 | 1 |
| Santen Pharmaceutical Co., Ltd. | 57 | 1 |
| SynDevRx, Inc. | 58 | 1 |
| TopiVert Ltd | 59 | 1 |
| TxCell SA | 60 | 1 |
| Uveitis Therapeutics Assessment | 61 | 11 |
| Assessment by Monotherapy Products | 61 | 1 |
| Assessment by Target | 62 | 3 |
| Assessment by Mechanism of Action | 65 | 3 |
| Assessment by Route of Administration | 68 | 2 |
| Assessment by Molecule Type | 70 | 2 |
| Drug Profiles | 72 | 103 |
| 2-B3201 Drug Profile | 72 | 2 |
| abatacept Drug Profile | 74 | 5 |
| adalimumab Drug Profile | 79 | 8 |
| ANV-103 Drug Profile | 87 | 1 |
| ATXUV-1 Drug Profile | 88 | 1 |
| ATXUV-2 Drug Profile | 89 | 1 |
| B27-PD Drug Profile | 90 | 1 |
| BNC-164 Drug Profile | 91 | 1 |
| celecoxib Drug Profile | 92 | 2 |
| Col-Treg Drug Profile | 94 | 2 |
| CVX-001 Drug Profile | 96 | 1 |
| cyclosporine SR Drug Profile | 97 | 1 |
| dalazatide Drug Profile | 98 | 5 |
| dexamethasone acetate Drug Profile | 103 | 4 |
| dexamethasone acetate Drug Profile | 107 | 1 |
| dexamethasone acetate Drug Profile | 108 | 1 |
| dexamethasone sodium phosphate Drug Profile | 109 | 2 |
| Drug for Chronic Uveitis Drug Profile | 111 | 1 |
| Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders Drug Profile | 112 | 1 |
| EBI-031 Drug Profile | 113 | 1 |
| EC-1669 Drug Profile | 114 | 1 |
| EYS-606 Drug Profile | 115 | 1 |
| fluocinolone acetonide SR Drug Profile | 116 | 8 |
| FR-104 Drug Profile | 124 | 3 |
| Gene Therapy for Dry Age-Related Macular Degeneration and Uveitis Drug Profile | 127 | 1 |
| HL-036 Drug Profile | 128 | 1 |
| HO-10 Drug Profile | 129 | 1 |
| INV-17 Drug Profile | 130 | 1 |
| IVMED-10 Drug Profile | 131 | 1 |
| IVMED-20 Drug Profile | 132 | 1 |
| KPI-190 Drug Profile | 133 | 1 |
| LME-636 Drug Profile | 134 | 1 |
| lodamin Drug Profile | 135 | 1 |
| methotrexate Drug Profile | 136 | 1 |
| NOP-3 Drug Profile | 137 | 1 |
| NS-2 Drug Profile | 138 | 4 |
| OX-1001 Drug Profile | 142 | 1 |
| piclidenoson Drug Profile | 143 | 8 |
| PL-8177 Drug Profile | 151 | 1 |
| plastoquinone decyl triphenylphosphonium bromide Drug Profile | 152 | 2 |
| PP-001 Drug Profile | 154 | 1 |
| PPL-003 Drug Profile | 155 | 2 |
| Recombinant Enzymes for Uveitis Drug Profile | 157 | 1 |
| sarilumab Drug Profile | 158 | 5 |
| sirolimus Drug Profile | 163 | 2 |
| Small Molecules to Inhibit 5-Lipoxygenase for Uveitis Drug Profile | 165 | 1 |
| Stem Cell Therapy for Autoimmune Diseases Drug Profile | 166 | 2 |
| tesidolumab Drug Profile | 168 | 2 |
| TOP-1288 Drug Profile | 170 | 1 |
| triamcinolone acetonide Drug Profile | 171 | 4 |
| Uveitis Dormant Projects | 175 | 4 |
| Uveitis Discontinued Products | 179 | 1 |
| Uveitis Product Development Milestones | 180 | 13 |
| Featured News &Press Releases | 180 | 1 |
| Sep 12, 2016: EyeGate Pharmaceuticals Receives Additional Milestone Payment from Valeant Pharmaceuticals for EGP-437 | 180 | 1 |
| Aug 15, 2016: Topline Results from First Phase 3 Trial of pSividas Medidur Presented at ASRS Annual Meeting | 180 | 1 |
| Aug 09, 2016: Primary Endpoint Met in pSivida's Utilization Study of New Medidur Inserter with Smaller Diameter Needle | 181 | 1 |
| Aug 03, 2016: Clearside Biomedical to Present Data from Phase 2 (DOGWOOD) Clinical Trial for the Treatment of Macular Edema Associated with Non-Infectious Uveitis at the 2016 ASRS Annual Meeting | 181 | 1 |
| Jul 27, 2016: pSivida's Medidur Maintains Same High Statistical Significance in Primary Endpoint through 12 Months in First Phase 3 Trial (p Less Than 0.00000001) | 182 | 1 |
| Jul 27, 2016: Mitotech announces its Ophthalmic Scientific Advisory Board | 183 | 1 |
| Jul 14, 2016: Investigator-Sponsored Phase 2 Study Results Show pSivida s Medidur Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve | 184 | 1 |
| Jul 14, 2016: Investigator-Sponsored Phase 2 Study Results Show pSivida s Medidur Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve | 185 | 1 |
| Jul 07, 2016: Eleven Biotherapeutics Announces Effectiveness of Investigational New Drug Application for EBI-031 | 185 | 1 |
| Jun 30, 2016: AbbVie's HUMIRA (adalimumab) Receives U.S. Food and Drug Administration Approval to Treat Adults with Non-Infectious Intermediate, Posterior and Panuveitis | 186 | 1 |
| Jun 02, 2016: AbbVie's Research and Commitment to Helping People Living with Rheumatologic Diseases Highlighted at the Annual European Congress of Rheumatology | 187 | 2 |
| May 27, 2016: AbbVie HUMIRA (adalimumab) Receives CHMP Positive Opinion to Treat Certain Forms of Non-Infectious Uveitis, a Disease that Can Severely Impact Vision | 189 | 1 |
| May 27, 2016: Santen Oy Withdraw an application for a change to the marketing authorisation for Opsiria (sirolimus) | 190 | 1 |
| May 26, 2016: Palatin Technologies Receives Patent Strengthening Its Melanocortin Peptide Intellectual Property | 191 | 1 |
| May 09, 2016: Aldeyra Therapeutics Announces Positive Results From Phase II Clinical Trial in Subjects With Noninfectious Anterior Uveitis | 191 | 2 |
| Appendix | 193 | 2 |
| Methodology | 193 | 1 |
| Coverage | 193 | 1 |
| Secondary Research | 193 | 1 |
| Primary Research | 193 | 1 |
| Expert Panel Validation | 193 | 1 |
| Contact Us | 193 | 1 |
| Disclaimer | 194 | 1 |